Grendene S.A (GRND3) - Net Assets
Based on the latest financial reports, Grendene S.A (GRND3) has net assets worth R$4.05 Billion BRL (≈ $794.83 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$4.52 Billion ≈ $887.87 Million USD) and total liabilities (R$474.16 Million ≈ $93.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Grendene S.A (GRND3) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$4.05 Billion |
| % of Total Assets | 89.52% |
| Annual Growth Rate | 11.04% |
| 5-Year Change | -4.47% |
| 10-Year Change | 54.43% |
| Growth Volatility | 12.39 |
Grendene S.A - Net Assets Trend (2000–2024)
This chart illustrates how Grendene S.A's net assets have evolved over time, based on quarterly financial data. Also explore Grendene S.A assets under control for the complete picture of this company's asset base.
Annual Net Assets for Grendene S.A (2000–2024)
The table below shows the annual net assets of Grendene S.A from 2000 to 2024. For live valuation and market cap data, see Grendene S.A market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | R$4.04 Billion ≈ $792.91 Million |
+10.43% |
| 2023-12-31 | R$3.66 Billion ≈ $718.05 Million |
-16.15% |
| 2022-12-31 | R$4.36 Billion ≈ $856.32 Million |
+6.59% |
| 2021-12-31 | R$4.09 Billion ≈ $803.38 Million |
-3.21% |
| 2020-12-31 | R$4.23 Billion ≈ $830.04 Million |
+5.58% |
| 2019-12-31 | R$4.01 Billion ≈ $786.19 Million |
+15.63% |
| 2018-12-31 | R$3.47 Billion ≈ $679.90 Million |
+7.69% |
| 2017-12-31 | R$3.22 Billion ≈ $631.35 Million |
+10.11% |
| 2016-12-31 | R$2.92 Billion ≈ $573.36 Million |
+11.67% |
| 2015-12-31 | R$2.62 Billion ≈ $513.46 Million |
+12.41% |
| 2014-12-31 | R$2.33 Billion ≈ $456.78 Million |
+12.57% |
| 2013-12-31 | R$2.07 Billion ≈ $405.77 Million |
+5.86% |
| 2012-12-31 | R$1.95 Billion ≈ $383.32 Million |
+8.47% |
| 2011-12-31 | R$1.80 Billion ≈ $353.38 Million |
+7.48% |
| 2010-12-31 | R$1.68 Billion ≈ $328.80 Million |
+14.41% |
| 2009-12-31 | R$1.46 Billion ≈ $287.37 Million |
+11.11% |
| 2008-12-31 | R$1.32 Billion ≈ $258.63 Million |
+11.66% |
| 2007-12-31 | R$1.18 Billion ≈ $231.62 Million |
+20.55% |
| 2006-12-31 | R$979.23 Million ≈ $192.14 Million |
+15.05% |
| 2005-12-31 | R$851.17 Million ≈ $167.01 Million |
+15.45% |
| 2004-12-31 | R$737.29 Million ≈ $144.67 Million |
+6.43% |
| 2003-12-31 | R$692.73 Million ≈ $135.93 Million |
+56.72% |
| 2002-12-31 | R$442.00 Million ≈ $86.73 Million |
+29.20% |
| 2001-12-31 | R$342.11 Million ≈ $67.13 Million |
+4.56% |
| 2000-12-31 | R$327.18 Million ≈ $64.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Grendene S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | R$120.56 Million | 2.98% |
| Common Stock | R$2.26 Billion | 55.83% |
| Other Comprehensive Income | R$1.66 Billion | 41.18% |
| Other Components | R$1.00 | 0.00% |
| Total Equity | R$4.04 Billion | 100.00% |
Grendene S.A Competitors by Market Cap
The table below lists competitors of Grendene S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MBK Public Company Limited
BK:MBK-R
|
$775.40 Million |
|
Suzhou Tianwo Science and Technology Co Ltd
SHE:002564
|
$775.47 Million |
|
MedCap AB (publ)
ST:MCAP
|
$775.50 Million |
|
Zhongzhu Medical Holdings Co Ltd
SHG:600568
|
$775.71 Million |
|
Karnov Group AB
ST:KAR
|
$775.03 Million |
|
Zhejiang Starry Pharm Co Ltd
SHG:603520
|
$774.97 Million |
|
Runner Xiamen Corp
SHG:603408
|
$774.79 Million |
|
Kura Oncology Inc
NASDAQ:KURA
|
$774.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Grendene S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,659,443,000 to 4,040,946,000, a change of 381,503,000 (10.4%).
- Net income of 735,236,000 contributed positively to equity growth.
- Dividend payments of 219,417,000 reduced retained earnings.
- Share repurchases of 3,036,000 reduced equity.
- New share issuances of 1,977,000 increased equity.
- Other comprehensive income decreased equity by 763,904,001.
- Other factors increased equity by 630,647,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$735.24 Million | +18.19% |
| Dividends Paid | R$219.42 Million | -5.43% |
| Share Repurchases | R$3.04 Million | -0.08% |
| Share Issuances | R$1.98 Million | +0.05% |
| Other Comprehensive Income | R$-763.90 Million | -18.9% |
| Other Changes | R$630.65 Million | +15.61% |
| Total Change | R$- | 10.43% |
Book Value vs Market Value Analysis
This analysis compares Grendene S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.98x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.69x to 0.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | R$0.77 | R$4.38 | x |
| 2004-12-31 | R$0.82 | R$4.38 | x |
| 2005-12-31 | R$0.95 | R$4.38 | x |
| 2006-12-31 | R$1.09 | R$4.38 | x |
| 2007-12-31 | R$1.31 | R$4.38 | x |
| 2008-12-31 | R$1.46 | R$4.38 | x |
| 2009-12-31 | R$1.63 | R$4.38 | x |
| 2010-12-31 | R$1.86 | R$4.38 | x |
| 2011-12-31 | R$2.00 | R$4.38 | x |
| 2012-12-31 | R$2.16 | R$4.38 | x |
| 2013-12-31 | R$2.28 | R$4.38 | x |
| 2014-12-31 | R$2.57 | R$4.38 | x |
| 2015-12-31 | R$2.90 | R$4.38 | x |
| 2016-12-31 | R$3.24 | R$4.38 | x |
| 2017-12-31 | R$3.56 | R$4.38 | x |
| 2018-12-31 | R$3.84 | R$4.38 | x |
| 2019-12-31 | R$4.44 | R$4.38 | x |
| 2020-12-31 | R$4.69 | R$4.38 | x |
| 2021-12-31 | R$4.54 | R$4.38 | x |
| 2022-12-31 | R$4.84 | R$4.38 | x |
| 2023-12-31 | R$4.06 | R$4.38 | x |
| 2024-12-31 | R$4.48 | R$4.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Grendene S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.19%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.30%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.11x
- Recent ROE (18.19%) is below the historical average (18.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 20.72% | 14.13% | 1.08x | 1.36x | R$34.73 Million |
| 2001 | 28.32% | 16.60% | 1.16x | 1.47x | R$61.97 Million |
| 2002 | 26.81% | 15.51% | 1.04x | 1.66x | R$73.46 Million |
| 2003 | 29.34% | 19.15% | 1.15x | 1.33x | R$133.95 Million |
| 2004 | 9.18% | 5.58% | 1.15x | 1.42x | R$-6.07 Million |
| 2005 | 10.03% | 8.00% | 0.92x | 1.36x | R$284.00K |
| 2006 | 13.79% | 12.24% | 0.78x | 1.45x | R$37.10 Million |
| 2007 | 10.68% | 10.47% | 0.81x | 1.26x | R$7.99 Million |
| 2008 | 18.17% | 19.15% | 0.76x | 1.25x | R$107.60 Million |
| 2009 | 18.59% | 18.70% | 0.83x | 1.20x | R$125.77 Million |
| 2010 | 18.65% | 19.47% | 0.80x | 1.19x | R$144.94 Million |
| 2011 | 16.96% | 20.60% | 0.72x | 1.14x | R$125.39 Million |
| 2012 | 21.97% | 22.79% | 0.82x | 1.17x | R$233.77 Million |
| 2013 | 21.04% | 19.82% | 0.92x | 1.15x | R$227.47 Million |
| 2014 | 21.17% | 21.95% | 0.83x | 1.16x | R$258.71 Million |
| 2015 | 21.07% | 25.02% | 0.72x | 1.16x | R$289.57 Million |
| 2016 | 21.71% | 31.02% | 0.63x | 1.11x | R$342.29 Million |
| 2017 | 20.54% | 29.35% | 0.63x | 1.11x | R$339.17 Million |
| 2018 | 16.90% | 25.09% | 0.60x | 1.11x | R$239.03 Million |
| 2019 | 20.45% | 39.56% | 0.46x | 1.13x | R$418.55 Million |
| 2020 | 9.58% | 21.36% | 0.41x | 1.11x | R$-17.81 Million |
| 2021 | 14.68% | 25.66% | 0.51x | 1.11x | R$191.57 Million |
| 2022 | 13.02% | 22.61% | 0.52x | 1.10x | R$131.61 Million |
| 2023 | 15.24% | 22.92% | 0.60x | 1.11x | R$191.73 Million |
| 2024 | 18.19% | 30.30% | 0.54x | 1.11x | R$331.14 Million |
Industry Comparison
This section compares Grendene S.A's net assets metrics with peer companies in the Footwear & Accessories industry.
Industry Context
- Industry: Footwear & Accessories
- Average net assets among peers: $1,117,285,000
- Average return on equity (ROE) among peers: 8.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Grendene S.A (GRND3) | R$4.05 Billion | 20.72% | 0.12x | $775.35 Million |
| Alpargatas S.A (ALPA3) | $2.26 Billion | 16.00% | 0.70x | $739.46 Million |
| Vulcabras Azaleia S.A (VULC3) | $-29.82 Million | 0.00% | 0.00x | $972.59 Million |
About Grendene S.A
Grendene S.A., together with its subsidiaries, engages in the development, production, distribution, and sale of plastic footwear for women, men, and children in Brazil and internationally. The company sells its products through its stores, franchised stores, and web commerce channels, as well as through commercial representatives and distributors under the Melissa, Grendha, Rider, Cartago, Ipane… Read more